Novo Nordisk needs to turn itself around. Eli Lilly doesn't. That's the story here.
Analysts are watching two companies fight over who gets to charge obese people monthly subscriptions for the rest of their lives. Lilly currently wins because analysts say so. Novo trails behind because analysts also say so. The drugs do the same thing. The stocks move on vibes.
Retail traders saw GLP-1 in a headline eighteen months ago and decided it was their entire personality. They bought Novo at the top. They bought Lilly higher. They will buy whichever one CNBC mentions tomorrow at 9:47 a.m. Eastern. They do not know what GLP-1 stands for. They do not care. They saw Oprah lose weight and decided that was a signal.
The funniest part is the framing. Novo works to turn itself around. As if this company is a struggling restaurant in Dayton that just hired a new chef. Novo Nordisk has a market cap north of $400 billion. It prints money by selling diabetes drugs to Americans who eat themselves into metabolic failure. Now it needs a turnaround because another company that does the exact same thing has better quarterly optics.
Lilly has advantages, according to analysts. Not better science. Not cheaper production. Advantages. The kind you quantify in a fourteen-page equity research report that three people read and one person trades on. The advantage is that analysts like Lilly more this quarter. Next quarter they will release another report explaining why Novo has advantages. The drugs still do the same thing.
Every day another middle-aged man in New Jersey checks his Robinhood account and whispers "GLP-1s" like it's a f*cking spell. He has no idea which company makes which drug. He bought both. He will sell neither. He believes he is investing in the future. He is paying rent on someone else's yacht.
The obesity drug market has a top. Lilly sits there. Novo chases. Your portfolio does neither.
Photo by on Unsplash
Leave a Comment